All News

lupus.GN_.jpg

Obintuzumab in Lupus Nephritis

d EurekAlert

In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney con

Read Article
RheumNow Podcast square

ACR Convergence Preview (11.10.2023)

d Jack Cush, MD

Dr. Jack Cush reviews this past week's news on RheumNow.com and suggests a learning plan for those wanting to consume the upcoming ACR Convergence 2023 meeting. 

Read Article
synovitis2.JPG

Rheumatoid Synovium Characterized by Six Cell Type Phenotypes

d Jack Cush, MD

Research work from the Accelerating Medicines Partnership (AMP: RA/SLE) Network, was published in Nature and more specifically characterizes RA synovium into several cell-type abundance phenotypes (CTAPs). Could CTAPs known disease features or more effective future therapies? 

Read Article
joint.pain_.hand_.PIP_.jpg

Arthritis Increased Amongst US Veterans

d CDC

A recent CDC reports estimates that in 2019–2021, 21% of U.S. adults (53.2 million) have physician diagnosed arthritis. Now, an updated report shows a larger number (~33%) of U.S. veterans having diagnosed arthritis. Compared to nonveterans, this prevalence was double in men, and 60% higher in women.

Read Article
RA erosions bone ACR

AI Identifies and Predicts Radiographic Change in Rheumatoid Arthritis

d ACR

The American College of Rheumatology's (ACR) has published a preview of new research from ACR Convergence 2023 showing that AI and a deep learning system could accurately identify and predict joint space narrowing and erosions in hand radiographs of patients with rheumatoid arthritis (RA).

Read Article
Xray.hand__0.jpg

X-Rays Questioned for Diagnosing Early Rheumatoid Arthritis

d MedPage Today

Routine hand and foot radiographs in more than 700 patients being evaluated for rheumatoid arthritis (RA) made almost no difference in diagnosing the condition nor in predicting its course, Dutch researchers said.

Read Article
Dr. Iyer - factors driving inequity in the access of essential medicines esp. in low to middle-income countries: 💠availability 💠affordability 💠accessibility 💠acceptability #ACR23 @RheumNow @rheumarhyme https://t.co/eIvOAjg31H
sheila  ( View Tweet)
Inequities in Medical Care Delivery: 👉>80% of people live in low/middle income places 👉2 billion people are unable to access meds and healthcare services 👉Availability, accessibility, affordability, acceptability are the 4 barriers Dr. J Iyer #ACR23 @RheumNow #GlobalSummit https://t.co/u21NTAYBpY
TheDaoIndex KDAO2011 ( View Tweet)
Big Pharma – Pay attention! When developing new therapeutics, consider delivery, cost, climate sensitivity and sustainability #GlobalSummit @ACRheum @rheumnow #ACR23 https://t.co/ThqnTI3SNm
TheDaoIndex KDAO2011 ( View Tweet)
Opportunities to address healthcare inequities: generics/biosimilars, fair pricing, and inclusive business models. #GlobalSummit @RheumNow #ACR23 @ACRheum https://t.co/ynJWWcCqWo
TheDaoIndex KDAO2011 ( View Tweet)
Retrospective study(2016-2019) of referred newly, suspected (#RA) pts found no value in initial Xrays. Only 32/724 patients (4.4%) had RA like erosions, with Erosions leading to a Dx in only 2 pts (0.3%) & changed prognostic classification in 3 pts (0.4%) https://t.co/fi48WiBgIc https://t.co/skObArXYr6

Links:

Dr. John Cush RheumNow ( View Tweet)
Orthopedic cohort study of 274,403 pts (180K females, 94K males; mean age=55). The risk of future TKA was signif greater in pts w/ combination of Depression+Obesity group (11.9%); compared to Controls (8.3%), obese (10.2%) or Depression (7.8%) https://t.co/dltVS0Y6PY https://t.co/REgO5tjEUv

Links:

Dr. John Cush RheumNow ( View Tweet)
RHEUM SURVEY: Your choice of a biologic in SpA patients is mostly influenced by? Respond here>> https://t.co/AtX4vZBvIT https://t.co/CgzROe8irB

Links:

Dr. John Cush RheumNow ( View Tweet)
Introducing RheumNow's #ACR23 faculty! They'll be covering ACR this weekend with valuable tweets, articles, videos and more. Follow us for real time updates. https://t.co/c9jla43lqw
Dr. John Cush RheumNow ( View Tweet)
QD Clinics - Neighbor Consults Your neighbor has a Swollen RPIP4. QD Clinics are sponsored by RheumNows Coverage of #ACR23 live from San Diego https://t.co/ZXNalfiVFv https://t.co/TAxpVyowF5

Links:

Dr. John Cush RheumNow ( View Tweet)
Patients Don't Read Textbooks RA patient unresponsive to biologics, now has enthesitis; what to do? QD Clinics are sponsored by RheumNows Coverage of #ACR23 live from San Diego https://t.co/hlacYXm0Nh https://t.co/52Xy3E8kXi

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Reacts to 2024 Medicare Physician Fee Schedule The ACR expressed concern that the conversion factor included in the CMS CY 2024 Medicare Physician Fee Schedule and Quality Payment Program final rule is insufficient to address rising inflation https://t.co/ZkMdqJEOkm https://t.co/70SxSGckGf

Links:

Dr. John Cush RheumNow ( View Tweet)
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions. https://t.co/MRFwrCXIlQ https://t.co/Su3nMs4CNW

Links:

Dr. John Cush RheumNow ( View Tweet)
2023 Medscaped Female Compensation Survey asked What percentage would again chose their specialty ? Top 5 specialties rechosen: Cardiology: 82% & Dermatology: 82% Psychiatry: 81% Allergy and immunology: 80% Neurology: 79% Rheumatology: 78% https://t.co/Zy4AJzb7dn. https://t.co/m9HjQ4T5aW

Links:

Dr. John Cush RheumNow ( View Tweet)
Long term results of the MAINRITSAN study (Maintenance Remission w/ RTX in Systemic AAV) showed fixed-schedule RTX superior to AZA in preventing major relapses at 84mos (HR 0.38), but tailored-RTX assoc w/ incr risk of major relapse (HR 2.92) https://t.co/xLxvPCsRC9 https://t.co/mWwo7GgCIq

Links:

Dr. John Cush RheumNow ( View Tweet)
×